XENIKOS

During this difficult time, we wish to extend our sincere gratitude to the patients and their families, as well as our employees, investors, and partners for their support throughout this journey. Even though T-Guard did not reach the end of Phase 3 testing, we believe that our data will contribute to future research regarding this and other devastating diseases. It is also currently being explored whether T-Guard can be further developed for other clinical indications.

Also known as: Xenikos B.V.